Search
Strontium chloride Sr-89
go.drugbank.com/drugs/DB09498ApprovedIt is usually presented mainly in patients with prostatic and breast cancer, as well as in cancer of lung, bladder and thyroid. … Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer.[A31264] Bone metastases is a common and severe complication presented in advanced stages of the disease.
Technetium Tc-99m oxidronate
go.drugbank.com/drugs/DB09139ApprovedWithdrawnA radiopharmaceutical is defined as a medicinal formulation containing radioisotopes that are used in major clinical areas for diagnosis and/or therapy. … [L1140] It was developed by Mallinkrodt nuclear and FDA approved on February 18, 1981.
Iloperidone
go.drugbank.com/drugs/DB04946ApprovedInvestigationalIloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009. … [A3024] It is considered to be a second-generation antipsychotic drug [A263552] with multiple receptor binding profile, although it shows high affinity towards 5-HT<sub>2A</sub> and dopamine D2 receptors
Hetacillin
go.drugbank.com/drugs/DB00739ApprovedVet approvedWithdrawnHetacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. … Hetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria.
Tetraferric tricitrate decahydrate
go.drugbank.com/drugs/DB14520ApprovedInvestigationalTetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. … [A25965] Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014.[L9926]
Glasdegib
go.drugbank.com/drugs/DB11978ApprovedInvestigationalCurrently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due … [L11935] Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade.
Bulevirtide
go.drugbank.com/drugs/DB15248ApprovedInvestigationalIt was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency. … Completion of this clinical trial is anticipated in early 2023.[L30240]
Anethole trithione
go.drugbank.com/drugs/DB13853Approvedhepatitis [L2388] and is marketed in certain countries like France, Germany, and China [A32614]. … for many of these aforementioned functions at this time and is only used in limited regions around the world.
Elexacaftor
go.drugbank.com/drugs/DB15444ApprovedInvestigational[A187361] It received FDA approval in October 2019 in combination with [tezacaftor] and [ivacaftor] as the combination product Trikafta<sup>TM</sup>. … [A187361] While dual corrector/potentiator combination therapy has proven useful in the treatment of a subset of CF patients,[A187358] their use is typically limited to patients who are homozygous for
Nerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigational[L54858] In the Phase 3 FIBRONEER-ILD trial, nerandomilast led to a smaller decline in forced vital capacity (FVC) than placebo over 52 weeks. [A274591] … [L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade.